Reciprocity and the Nagoya Protocol in Psychedelic Therapy
Christine Diindsiisi McCleave, PhD (Strategic Relationships Advisor for IMC Fund)
Tuesday 30 June, 2026 8PM CEST (7PM BST, 2PM ET, 11AM PT)
Online via Zoom
Add to Calendar
A PsyPal (Horizon Europe) & OPEN Foundation collaboration
As psychedelic therapies move into global clinical and commercial contexts, questions of reciprocity, responsibility, and relationship are rising to the forefront. Central to these conversations is the Nagoya Protocol — an international framework designed to ensure fair and equitable sharing of benefits arising from the use of biological resources and associated traditional knowledge.
This talk is led by Christine Diindiisi McCleave, citizen of the Turtle Mountain Anishinaabe (Ojibwe) Nation, and former CEO of the National Native American Boarding School Healing Coalition. She is currently the Strategic Relationships Advisor for the Indigenous Medicine Conservation Fund. Drawing on legal, ethical, and relational dimensions, she will offer a grounded exploration of what reciprocity can look like in the psychedelic field today, and what it asks of those working within it.
Together, we’ll explore areas where different interpretations commonly arise: why the Nagoya Protocol was developed, what it seeks to address in relation to traditional knowledge and biocultural resources, and how it applies to both plant-derived and synthetic compounds. The discussion will also consider how industrial and biomedical approaches can engage these complexities in ways that build trust and support long-term ethical relationship across different knowledge systems.
Structured as a talk followed by moderated Q&A, this free, open-access event is designed for listening, learning, and thoughtful dialogue. It aims to create space for Indigenous voices to speak from their own perspectives, while inviting clinicians, researchers, and industry participants into a deeper understanding of reciprocity — one that extends beyond compliance toward genuine, lasting relationship.
About PsyPal
PsyPal is the first EU-funded multisite psilocybin therapy clinical trial project, dedicated to identify paths for implementation in society, including all stakeholders. PsyPal aims to treat existential distress/depression in patients suffering from life-shortening disease such as COPD, ALS, Parkinson or MS.